BYM338 vs Epoetin Alfa
Head-to-head comparison of BYM338 (Bimagrumab (BYM338)) and Epoetin Alfa (Recombinant human erythropoietin alfa) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | BYM338 | Epoetin Alfa |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Bimagrumab (BYM338) | Recombinant human erythropoietin alfa |
| Molecular Weight | ~148 kDa | ≈30,400 Da |
| Half-Life | ~2-3 weeks | ~4-13 h IV; ~20-30 h SC |
| Amino Acids | N/A | 165 |
| Typical Dose | 10-30 mg/kg IV in trials | 50-100 IU/kg SC 3x weekly or 40,000 IU SC weekly |
| Route | Intravenous | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 140 | 320 |
| Research Status | Clinical | Clinical |
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Epoetin Alfa Benefits
- ✓raises hemoglobin
- ✓increases oxygen-carrying capacity
- ✓may increase VO2 max
- ✓improves time-to-exhaustion
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Epoetin Alfa Dosing
50-100 IU/kg subcutaneous 3x weekly|40,000 IU subcutaneous weekly|Titrate to hemoglobin target under medical supervision
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Epoetin Alfa Side Effects
- ⚠hypertension
- ⚠thrombosis
- ⚠polycythemia
Research Overview
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Epoetin Alfa
Human studies in anemia and performance-related settings show that increasing red-cell mass can improve aerobic capacity and endurance. It remains heavily regulated because excessive erythropoiesis raises thrombotic and cardiovascular risk.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.